Diagnostics division to help Lilly tailor treatments
Eli Lilly and Co. is launching a diagnostics division to produce tests that can winnow out the patients most likely to benefit
from a Lilly drug.
Eli Lilly and Co.
Articles
Lilly’s Lechleiter: No change in plans
The global financial press keeps asking John Lechleiter for his end-game strategy to survive Eli Lilly and Co.'s nightmarish
patent challenges. And, like a broken record, the Lilly CEO keeps giving the same answer: pipeline, pipeline, pipeline—no
mega-merger.
Men on Viagra, Cialis show triple rate of sex diseases in study
The findings suggest that users of drugs to treat erectile dysfunction, including Eli Lilly’s Cialis, may be more likely to
engage in unsafe sex than nonusers.
Lilly acquires biotech company with pancreatic drug
Massachusetts-based Alnara Pharmaceuticals Inc., which has attracted $55 million in venture capital in the past two years,
recently submitted its drug to the FDA for market approval.
Grassley asks Lilly, peers about whistleblower treatment
U.S. Senator Charles Grassley asked 16 drugmakers, including Eli Lilly & Co., Pfizer Inc. and AstraZeneca Plc, to reveal
how they treat whistleblowers who file complaints under the False Claims Act.
Lilly’s Effient steps forward, then back
A day after doctors were alerted to a black-box warning that could slow sales of Effient’s main competitor,
Plavix,
a medical journal published research showing that patients suffered 43-percent more cancer tumors on Effient than on Plavix.
Marcadia enlists Lilly to help develop new diabetes drug
The two companies will jointly develop a short-acting glucagon drug, which they hope proves more convenient than Lilly’s
current Glucagon for patients with severe hypoglycemia.
Hoosier firms that rely on innovation pine for patent reform
One key change would grant patents to the first inventor to file an application, not the first who can prove to have made
the invention first.
Lilly, Amylin stock rises on drug postponement
Roche Holding AG’s decision to postpone its experimental diabetes drug is helping boost shares in Amylin Pharmaceuticals
Inc. and drug partner Eli Lilly and Co.
Lilly layoffs pare communications department
The giant drugmaker is in the process of trimming 35 percent—or about 19 people—from its 55-person communications
staff. Most of that staff is based in Indianapolis.
Slow economy bruises profits of Indiana’s largest public companies
One-time events influenced bottom lines of some of the few companies that made more money in 2009.
Recession hammered revenue of Indiana’s largest public companies
Few escaped the Great Recession unscathed, and unusual circumstances helped some appear as though they did.
Research reforms will force Lilly, others to test how drugs stack up
The federal government is currently doling out $1.1 billion in stimulus funds to pay for research that compares multiple medical
treatments against one another to determine which is most effective. Drug companies like Eli Lilly and Co. are wary that comparative-effectiveness
research could threaten their sales.
Lilly taps O’Connor as state lobbyist
O’Connor, chief deputy mayor under former Indianapolis Mayor Bart Peterson, started Monday as Lilly's director of
state government affairs—working again under Peterson.
Erbitux fails to stop colon cancer before it spreads
Eli Lilly and Co. and Merck KGaA drug failed to slow tumors in a study designed to expand the medicine’s use to patients whose
disease is in an earlier stage.
Genetic testing could spur Erbitux drug sales
The drugmakers are counting on screening for the so-called K-ras gene to spur use of Erbitux in metastatic colorectal cancer.
Lilly grows Alimta’s sales by shrinking market
In 2008, Eli Lilly and Co. asked drug regulators to change the label on Alimta so Lilly could no longer promote it as a treatment
for all patients suffering from non-small-cell lung cancer, but for only about 70 percent of the patients. Since then, sales
of the drug have accelerated, growing a whopping 48 percent last year.
Indianapolis startup attacks Alzheimer’s disease
AgeneBio Inc. this month landed a $300,000 investment from the Indiana Seed Fund to fund operations, bolster its intellectual
property, and begin learning how to make a drug into a once-a-day pill.
Lilly spent $2.3M lobbying in first quarter
Indianapolis-based Eli Lilly and Co. spent about $2.3 million in the first quarter of 2010 lobbying the federal government
on health care reform, Medicare reimbursement and trade issues among other topics.
Moody’s lowers Eli Lilly outlook to ‘negative’
Moody's Investors Service on Friday lowered its rating outlook on drugmaker Eli Lilly and Co. to "negative"
from "table" due in part to the looming expiration of patents protecting key drugs from generic competition.